BioMed Nexus Daily Updates
Your essential biotech, medtech, and pharma recap — no noise, just what matters.
Monday, November 9, 2026
📌TL;DR
Vir's Phase 3 ECLIPSE 1 met its primary endpoint in chronic hepatitis delta: 44% of patients on monthly elebsiran plus tobevibart reached undetectable virus and normal ALT at week 48, against 0% in the delayed arm at week 12; a US FDA submission is planned for mid 2027.
Natera named Solomon Moshkevich CEO effective immediately alongside its third quarter report; Steve Chapman steps down and stays on as a consultant and board adviser.
At ACR Convergence, CRISPR's off the shelf CAR T zugo-cel posted an 83% month 3 response in systemic sclerosis (5 of 6) with no CRS above Grade 2, and argenx's ALKIVIA met its combined myositis endpoint.
Regeneron's single dose CIDEB siRNA cut liver fat 58% to 80% at week 36 in fatty liver disease, published in NEJM.
J&J reported a 73% PSA50 response (11 of 15) for pasritamig plus JNJ-9401 in late line prostate cancer at SITC.
Tape: NTRA −14.6% on the CEO surprise, RYTM +6.9% on the bid, XBI +2.6% bounce.
⚡ Executive Takeaway
This market pays for what it can count and charges for surprise, whatever numbers come attached. Friday made the point three ways. Natera grew revenue 34% and raised its year by $140 million at the midpoint, then lost about a seventh of its value in one session because nobody saw a CEO change coming. Rhythm kept climbing with no company statement and two unreconciled offer prices around it, because a strategic buyer is a form of certainty public investors no longer supply themselves. And a fresh accelerated approval lifted Johnson & Johnson on a tape still recovering from Thursday's rout.
Vir walks into that market this morning with the cleanest kind of news: a pivotal trial that hit, a filing window, and two more Phase 3 readouts dated for the first quarter. The question for the session is not whether 44% is good. It is whether a dated regulatory path now earns a premium on its own, with no buyer attached.
This week's through line: the certainty premium. Vir today, Regeneron's Tuesday roundtable and the ObesityWeek data that start Saturday test whether data alone still clears higher.
🧬 Hepatitis Delta Gets Its First Pivotal Win for a Monthly Combination
Vir's elebsiran plus tobevibart met the ECLIPSE 1 primary endpoint, and the company now has a dated path to the FDA in the most severe form of viral hepatitis. VIR
ECLIPSE 1 randomized 124 patients 2:1 to monthly subcutaneous elebsiran, a small interfering RNA, plus tobevibart, an antibody against hepatitis B surface antigen, or to delayed treatment starting at week 12. The primary endpoint was strict: undetectable hepatitis delta virus RNA and normal ALT together. The population was broad and multi country, and more than half the treated arm had cirrhosis.
Endpoint | Treated, week 48 (n=83) | Delayed, week 12 (n=41) |
|---|---|---|
Undetectable virus plus normal ALT (primary) | 44% | 0% |
Undetectable virus (key secondary) | 79% | 0% |
Undetectable virus, cirrhotic (n=46) | 85% | n/a |
Undetectable virus, non cirrhotic (n=37) | 73% | n/a |
ALT normalization | 53% | 5% |
Read the design before the headline: the treated arm is measured at week 48 and the comparator at week 12, so the 0% is a delayed start, not a head to head. Safety was clean on the release's terms, one Grade 3 treatment related event and no discontinuations. Vir plans a US submission in mid 2027, with ECLIPSE 2 and the head to head ECLIPSE 3 against bulevirtide both reading in the first quarter. The release crossed Sunday at 4:15 pm ET, so today is the first reaction session; the stock closed Friday at $12.21, up 10.8% before any data.
🔬 Natera Beat, Raised and Changed CEOs in One Afternoon
Natera reported 34.1% revenue growth and raised its 2026 guide by $140 million at the midpoint, and the market priced the unexpected succession over all of it. NTRA
Third quarter revenue was $794.0 million, oncology tests processed rose 60.9% to about 339,500, and 2026 revenue guidance moved to $3.005 to $3.035 billion from $2.850 to $2.910 billion, all per Thursday's release. In a separate release the same afternoon, Solomon Moshkevich, President of Clinical Diagnostics and at Natera since 2011, became CEO effective immediately, and Steve Chapman stepped down to an extended consulting role and board adviser seat. No reason was given beyond Chapman calling it the right time. Analysts at TD Cowen, BNP Paribas and Canaccord tied Friday's drop to the surprise, per MedTech Dive. The stock closed at $310.67, down 14.6%, our arithmetic.
💊 Rhythm Climbs Again With Both Companies Silent
Rhythm rose 6.9% Friday to $112.28, now 29.9% above its pre report close, while AstraZeneca's reported approach stays unconfirmed. RYTM | AZN
The spread is narrowing: 10.4% to the Journal's $124 and 19.3% to Reuters' $134 including milestones, our arithmetic from Friday's close. Automated trade items cited reports of a second bidder; we could not trace that to a named outlet and are not treating it as established. We also found no release or filing confirming the $250 million credit draw Rhythm said it expected Friday (scope: searches Sunday night). The next hard datapoint is the final Phase 3 acquired hypothalamic obesity dataset at ObesityWeek, November 14 to 17.
🧪 Autoimmune Cell Therapy Shows Off the Shelf and One Year Data
ACR Convergence brought an allogeneic CAR T safety read from CRISPR, one year durability from Cabaletta, and a reminder from argenx that antibodies are moving faster. CRSP | CABA | ARGX | JNJ
CRISPR's zugo-cel has dosed 21 patients across lupus, systemic sclerosis and myositis, with no CRS above Grade 2, no ICANS and no deaths, an 83% month 3 rCRISS-25 response in systemic sclerosis and all nine myositis patients responding. Cabaletta's autologous rese-cel kept six of six dermatomyositis patients in response off immunomodulators through a year and plans a myositis BLA in the first quarter of 2028. argenx's ALKIVIA met its combined IMNM and dermatomyositis endpoint and heads to an IMNM sBLA by year end, though dermatomyositis alone missed significance (p=0.1093). J&J's oral icotrokinra hit ACR20 58% versus 41% placebo in psoriatic arthritis.
🩺 The Liver Meeting Closes on Genetics and Finite Therapy
A single dose of Regeneron's CIDEB siRNA cut liver fat 58% to 80% at week 36, and Vir's Phase 2 data opened the question of stopping therapy. REGN | VIR
Regeneron's 40 patient first in human study normalized liver fat in 62% of treated patients versus none on placebo, with simultaneous NEJM publication; CIDEB is a target picked from human loss of function genetics. Phase 2a, 2b and 3 trials are recruiting and the MASH roundtable is Tuesday. Separately, Vir's SOLSTICE showed undetectable virus in all 28 patients completing week 96, and in an exploratory group of 10 who stopped treatment, all reached SVR12 and seven SVR24. Ten patients is a hypothesis, not a claim.
📈 J&J Takes the Approval and Adds a Prostate Signal
Johnson & Johnson rose 1.4% in the first session after the Rybrevant Faspro approval and opened the weekend with early prostate cancer data. JNJ | XBI
At SITC, pasritamig plus JNJ-9401 produced a 73% PSA50 response in 11 of 15 patients at the recommended regimen, median four prior lines, with no Grade 3 or higher treatment related events; J&J itself calls the numbers preliminary, and a Phase 3 is underway. The sector bounced partway: XBI rose 2.6% to 152.21 after Thursday's 6.7% drop and the S&P 500 ETF added 0.3%. All closes are settled exchange prices and percentages are our arithmetic.
📋 Quick Hits
Veradermics hosts a call at 8:00 am ET today on 12 month results from Part B of its Phase 3 "302" hair loss study; Sunday's announcement carried no numbers, and this is the 302 study, not the 304 trial. MANE
Karyopharm shares are suspended from Nasdaq at the open Wednesday, November 11; they fell 8.7% Friday to $0.0549. KPTI
argenx presents ALKIVIA as a late breaking oral at ACR on November 11, 9:15 am ET. ARGX
Friday's poll: 14 readers answered what funds the gap if public markets stay shut. Seven chose pharma partnerships or M&A, four royalty or structured debt, two cutting to core assets, one said they are funded, and nobody picked private crossover rounds.
🗓️ What To Watch Today
November 9: Vir investor call on ECLIPSE 1 and SOLSTICE, 8:30 am ET (VIR)
November 10: Regeneron MASH pipeline roundtable, 8:30 am ET (REGN)
November 11: Karyopharm Nasdaq suspension at the open (KPTI)
📖 In Today's Full Analysis
Be sure to read the full article for all the details, including:
Every ECLIPSE 1 endpoint, including virologic response and HBsAg, and the filing timeline
Natera's full third quarter scorecard and the guidance walk
A side by side of four ACR Convergence datasets: CAR T, FcRn and an oral peptide
Friday's movers table and the Rhythm spread math
📋 The Week in Review
Monday: Inovio rose 214% in the first session after Voceryq's approval while rival Precigen fell 26%.
Tuesday: Karyopharm's Chapter 11 filing landed with a prepackaged plan that zeroes shareholders; Democrats swept the midterms after the close.
Wednesday: Healthcare repriced on the sweep and the Wall Street Journal reported AstraZeneca's $124 per share offer for Rhythm.
Thursday: The FDA approved Rybrevant Faspro after the close, the AI selloff erased the election rally, and Natera named a new CEO alongside a guidance raise.
Friday: Natera fell 14.6% on the succession, Rhythm added 6.9%, and XBI won back 2.6% of Thursday's loss.
🔒 BioMed Nexus Pro
In Today's Pro Brief...
🧠 What 44% actually buys in hepatitis delta, and which of Vir's three Phase 3s decides the commercial case
💊 The certainty premium: why a board's succession plan is now an operating metric, and the week's through line tests
📊 Off the shelf versus one year durable: the manufacturing and site of care math behind autoimmune CAR T
🎯 Plus the full catalyst calendar, rebuilt tonight: a delisting Wednesday, ObesityWeek, and a two week decision cluster

